BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32218621)

  • 21. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tuberous Sclerosis with Severe Cutaneous Manifestation and Multiples Facial Angiofibromas.
    Garcia NG; de Carli ML; Oliveira DT; Soares CT; Ribeiro Júnior NV; Sperandio FF; Hanemann JA
    Head Neck Pathol; 2016 Dec; 10(4):542-546. PubMed ID: 27140177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photodynamic therapy in a patient with facial angiofibromas due to tuberous sclerosis complex.
    Shi M; He S; Chen P; Li Q; Zhu M; Guo J; Jiang L; Wang Q; Peng X; Li S; Li C; Zeng K
    Photodiagnosis Photodyn Ther; 2019 Dec; 28():183-185. PubMed ID: 31398516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis.
    Weiss ET; Geronemus RG
    Lasers Surg Med; 2010 Jul; 42(5):357-60. PubMed ID: 20583249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
    Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
    Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
    Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cutaneous manifestations of tuberous sclerosis complex.
    Nguyen QD; DarConte MD; Hebert AA
    Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):321-325. PubMed ID: 30246432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unilateral facial angiofibromas without other evidence of tuberous sclerosis: case report and review of the literature.
    Hall MR; Kovach BT; Miller JL
    Cutis; 2007 Oct; 80(4):284-8. PubMed ID: 18038689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous markers of systemic manifestations of tuberous sclerosis complex.
    Galahitiyawa J; Wanigasinghe J; Seneviratne J; Galahitiyawa M
    Int J Dermatol; 2015 Jan; 54(1):e52-5. PubMed ID: 25534411
    [No Abstract]   [Full Text] [Related]  

  • 31. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
    Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
    Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uncommon Large and Bilateral Fibrous Cephalic Plaques in a Patient with
    González-Del Angel A; Ruiz-Herrera A; Hernández-Martínez NL; Todd-Quiñones CG; Durán-McKinster C; Herrera-Mora P; Alcántara-Ortigoza MA
    Children (Basel); 2023 Sep; 10(10):. PubMed ID: 37892277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unilateral multiple facial angiofibromas: a mosaic form of tuberous sclerosis.
    Silvestre JF; Bañuls J; Ramón R; Guijarro J; Botella R; Betlloch I
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):127-9. PubMed ID: 10863238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Angiofibromas on Quality of Life and Access to Care in Tuberous Sclerosis Patients and Their Caregivers.
    Crall C; Valle M; Kapur K; Dies KA; Liang MG; Sahin M; Huang JT
    Pediatr Dermatol; 2016 Sep; 33(5):518-25. PubMed ID: 27436143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Racial differences in the dermatological manifestations of tuberous sclerosis complex and the potential effects on diagnosis and care.
    Pounders AJ; Rushing GV; Mahida S; Nonyane BAS; Thomas EA; Tameez RS; Gipson TT
    Ther Adv Rare Dis; 2022; 3():26330040221140125. PubMed ID: 37180419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE; De Bernardis G; Weber P; Lösch U
    Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
    Dao DD; Pixley JN; Akkurt ZM; Feldman SR
    Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of twenty pediatric cases of tuberous sclerosis complex: are we doing enough?
    Nath J; Dubey A; Pavan R
    Indian J Dermatol Venereol Leprol; 2015; 81(1):23-8. PubMed ID: 25566892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
    Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
    Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of proteoglycans and glycosaminoglycans in angiofibroma and fibrous plaque skin lesions from patients with tuberous sclerosis.
    Papakonstantinou E; Dionyssopoulos A; Pesintzaki C; Minas A; Karakiulakis G
    Arch Dermatol Res; 2003 Aug; 295(4):138-45. PubMed ID: 12844226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.